Phenylketonuria Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Demand for Phenylketonuria Treatment Drugs
- Growing Advancements in Healthcare
Challenges
- High Cost of phenylketonuria treatment
Phenylketonuria Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.3% |
|
Base Year Market Size (2024) |
USD 794.16 million |
|
Forecast Year Market Size (2037) |
USD 1.98 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.
Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037.
North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria.
The major players in the market are Ultragenyx Pharmaceutical, PTC Therapeutics, BioMarin, Homology Medicines, Inc., SOM BIOTECH, Nestle Health Science, American Gene Technologies Inc., Rubius Therapeutics, Inc., Synlogic, and others.
